R223
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 118
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.690
- INTERFERON_GAMMA_RESPONSE+0.630
- ALLOGRAFT_REJECTION+0.560
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.530
- IL6_JAK_STAT3_SIGNALING+0.500
- TNFA_SIGNALING_VIA_NFKB+0.490
- INFLAMMATORY_RESPONSE+0.460
- APOPTOSIS+0.430
- COMPLEMENT+0.430
- HEDGEHOG_SIGNALING+0.390
Top 10 suppressed
- SPERMATOGENESIS-0.320
- MYC_TARGETS_V2-0.270
- PANCREAS_BETA_CELLS-0.260
- CHOLESTEROL_HOMEOSTASIS-0.140
- E2F_TARGETS-0.130
- G2M_CHECKPOINT-0.050
- KRAS_SIGNALING_DN-0.010
- OXIDATIVE_PHOSPHORYLATION-0.010
- BILE_ACID_METABOLISM+0.000
- GLYCOLYSIS+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_VP5Y45Z7 | pilocytic astrocytoma | — | 0.927 |
| 2 | SRR12696731 | — | — | 0.920 |
| 3 | 22DF9124-1DD5-4ED9-874E-2AB05A94F17E | — | — | 0.907 |
| 4 | BS_Z9ZS6ZS2 | MPNST | — | 0.906 |
| 5 | SRR934862 | — | — | 0.900 |
| 6 | 7E4D42B3-FD9B-4184-A4A0-E52E45259428 | — | — | 0.897 |
| 7 | R250 | — | — | 0.894 |
| 8 | BS_9HA238XS | Neurofibroma | — | 0.891 |
| 9 | BS_49VCQD19 | Neurofibroma | — | 0.890 |
| 10 | DACCA07A-8F2C-40C5-B8AD-73805E408D85 | — | — | 0.890 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.690 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.630 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.560 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.530 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.490 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.460 | Idelalisib | — uncovered |
| APOPTOSIS | 0.430 | Idelalisib | — uncovered |
| COMPLEMENT | 0.430 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.390 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.390 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.380 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.370 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.340 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.320 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.310 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.280 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.260 | Remibrutinib | — uncovered |